Andrew A. Hindman,
Chief Business Development Officer
Andrew A. Hindman joined Acorda in May 2014 as Chief Business Development Officer. Mr. Hindman is responsible for identifying and completing strategic transactions that expand the Company’s pipeline of commercial and development-stage products, as well as managing the Alliance Management function for existing partnerships.
Mr. Hindman has held several senior executive level positions in the biopharmaceutical industry, most recently as President, Chief Executive Officer and member of the Board of Tobira Therapeutics, a privately-held biotechnology company. At Tobira, he was responsible for developing a new corporate strategy, building new leadership and operational teams, and raising operating capital. Prior to Tobira, Mr. Hindman held senior corporate development and commercial operating positions at Nodality, Onyx Pharmaceuticals and Gilead Sciences.
Mr. Hindman holds a B.A. in biochemistry and economics, graduating Phi Beta Kappa, from Wesleyan University and an executive MBA from Columbia University and the University of California Berkeley, Haas School of Business.